Trials / Completed
CompletedNCT00814216
Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients
Randomized, Double-blind, Two Way Cross-over, Proof of Concept Study to Compare Efficacy, Safety, Pharmacokinetics & Pharmacodynamics of QAV680 Versus Placebo, With an Extended Open-label Corticosteroid Period, in Steroid-free, Mild to Moderate Persistent Asthma Patients.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to study the efficacy (as measured by change in FEV1) and safety of two-week administration of oral QAV680 in the treatment of patients with asthma.'
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAV680 | |
| DRUG | Matching placebo for QAV680 | |
| DRUG | Fluticasone Propionate |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-10-01
- First posted
- 2008-12-24
- Last updated
- 2017-03-08
Locations
7 sites across 2 countries: Germany, India
Source: ClinicalTrials.gov record NCT00814216. Inclusion in this directory is not an endorsement.